Trends, characteristics and treatment outcomes of patients with drug‐resistant tuberculosis in uzbekistan: 2013–2018

Abstract

Uzbekistan has a high burden of drug‐resistant tuberculosis (TB). Although conventional treatment for multidrug‐resistant TB (MDR‐TB) and extensively drug‐resistant TB (XDR‐TB) has been available since 2013, there has been no systematic documentation about its use and effective-ness. We therefore documented at national level the trends, characteristics, and outcomes of patients with drug‐resistant TB enrolled for treatment from 2013–2018 and assessed risk factors for unfavorable treatment outcomes (death, failure, loss to follow‐up, treatment continuation, change to XDR‐ TB regimen) in patients treated in Tashkent city from 2016–2017. This was a cohort study using secondary aggregate and individual patient data. Between 2013 and 2018, MDR‐TB numbers were stable between 2347 and 2653 per annum, while XDR‐TB numbers increased from 33 to 433 per annum. At national level, treatment success (cured and treatment completed) for MDR‐TB de-creased annually from 63% to 57%, while treatment success for XDR‐TB increased annually from 24% to 57%. On multivariable analysis, risk factors for unfavorable outcomes, death, and loss to follow‐up in drug‐resistant TB patients treated in Tashkent city included XDR‐TB, male sex, increas-ing age, previous TB treatment, alcohol abuse, and associated comorbidities (cardiovascular and liver disease, diabetes, and HIV/AIDS). Reasons for these findings and programmatic implications are discussed.